Navigation Links
Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
Date:5/12/2008

Results show promising neurological recovery in severely-injured, acute

cervical spinal cord injury patients treated with Cethrin

HOPKINTON, Mass., May 12 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced 12-month interim data from its Phase I/IIa clinical trial of Cethrin, a proprietary recombinant protein that is being investigated for its potential to restore motor and sensory function after spinal cord injury, or SCI. The trial enrolled a total of 48 patients of which 37 have reached the final 12 month follow up evaluation. The data for these first 37 patients indicate that at 6 and 12 months after treatment, 38% (5 of 13) of cervical injury patients showed marked recovery of motor and sensory function after treatment as measured by a 2-grade or better improvement in the American Spinal Injury Association, or ASIA, Impairment Scale. Analysis of the data by dose group indicates that Cethrin doses of 1 and 3 mg appear to be the most beneficial for cervical patients with 43% (3 of 7) showing the same 2-grade or better recovery of motor and sensory function.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )

"The safety and efficacy observations of the Cethrin trial continue to be encouraging. Many patients have shown a degree of improvement far above the expected outcome," commented Dr. Mark Hurtt, Alseres' Chief Medical Officer. "The interim results of the Phase I/IIa study have helped identify what we believe will be the most effective dose range to carry into our Phase IIb trial later this year."

Based on these results, Alseres intends to move forward with its previ
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
2. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
3. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
4. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
5. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
6. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
7. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine
8. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
9. Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
10. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
11. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...swire/--RemediumTechnologiesInc.,acompanydevelopin...firstprizeand$10,000intheMostPromisingSecurityIdea...ficialsannouncetoday. ,, Selectedfrommorethan10...eirinventionattheGSCSecuritySummitconferenceheldat...ediumtechnologies.com )isdevelopingahigh-pressuref...
(Date:11/25/2009)...stCall/--ChinaSkyOne,Medical,Inc.("ChinaSkyOneMedi...ntegratedpharmaceuticalcompanydevelopingandproduci...na("PRC"),today,announcedthattheCompanyrecentlypas...maceuticalandBiologicalProducts("ICPBP")examinatio...rostateSpecific,Antigen(ColloidalGold)anditsDeterm...
(Date:11/25/2009)...tCall/--Abaxis,Inc.(Nasdaq: ABAX ),amedicalproduct...tems,announcedtodaythatClintSeverson,chairmanandch...rJaffrayHealthCareConferenceonWednesday,December2,...rkPalaceHotelinNewYorkCity. ,, AboutAbaxis ,...loodanalysissystemsforuseinanyveterinaryorhumanpat...
Breaking Medicine Technology:Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 3According to Excel Physical Therapy and Fitness Awareness Still Low for Law that Allows People to go Directly to a Physical Therapist without a Docto 58347 1According to Excel Physical Therapy and Fitness Awareness Still Low for Law that Allows People to go Directly to a Physical Therapist without a Docto 58347 2According to Excel Physical Therapy and Fitness Awareness Still Low for Law that Allows People to go Directly to a Physical Therapist without a Docto 58347 3Does Helicobacter pylori eradication therapy prevent gastric cancer 3F 58344 1Does Helicobacter pylori eradication therapy prevent gastric cancer 3F 58344 2Environmental health chief in Milwaukee to hear citizen concerns 10107 1Environmental health chief in Milwaukee to hear citizen concerns 10107 2
... Primary Efficacy Endpoint Met in Stage 1 of Two-S...- 100% of Evaluable Patients to Date Continue to S...or Stable Disease -, TUSTIN, Calif., July 2 Pere... reported that its lead product,candidate bavituxi...point,in its ongoing Phase II clinical trial in pa...
...s show promise for ,buying time, in victims of let...TTLE, July 1 For the first time, researchers have...ounts of inhaled or,intravenous hydrogen sulfide, ...r sulfurous stench -- significantly improves survi...ist Mark B. Roth, Ph.D., and colleagues in the Bas...
Other Medicine Technology:Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer 2Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer 3Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer 4'Hibernation-On-Demand' Drug Hydrogen Sulfide Significantly Improves Survival After Extreme Blood Loss 2'Hibernation-On-Demand' Drug Hydrogen Sulfide Significantly Improves Survival After Extreme Blood Loss 3
(Date:11/25/2009)... plagued by neurological symptoms, study finds ,... Neurological side effects are among the potential...ar cancer who were treated with cisplatin-based ch...included 1,409 Norwegian men treated for unilatera... part in a follow-up survey conducted from 1998 to...
(Date:11/25/2009)...eImprovementShownforthe4thStraightYear ,, WAS...gCancerAlliance-Georgia(LCA-GA)issuedthe 4thAnnual...progressbeingmadeagainstthislethaldiseaseinthestat...A),theonlynationalorganizationdedicatedexclusively...riskforlungcancer. ,, (Logo: http://www.newscom...
(Date:11/25/2009)...placed under the skin kill tumor cells, study find...) -- A cancer vaccine delivered in a fingernail-si...ew study reports. , The method uses polymer dis...ith tumor-specific antigens and implanted under th...mors. The Harvard University scientists who develo...
(Date:11/25/2009)... BioSpace.com, the premier resource for ... third edition of the BioForest™ Hotbed Camp...ewood, CO (Vocus) November 25, 2009 -- BioSpace.co...nd information, unveiled the third edition of the ..., , ,This regional campaign is a promotional effo...
(Date:11/25/2009)...ECITY,Nov.25/PRNewswire/--dazzlesmile,llc www.dazz...lhealthscience.com havefileda67-pagefederallawsuit...Inc.,JesseWillms,FarendServicesLimited,andAtLastFu...tatesDistrictCourtfortheDistrictofUtah,allegesmass...le(TM)brandedteethwhiteningproducts,violationsofth...
Breaking Medicine News(10 mins):Health News:Lung Cancer Alliance-Georgia Issues 4th Annual State-Specific Report Card on Lung Cancer 2Health News:BioSpace Showcases Leading Life-Science Companies in the Northwest 2Health News:dazzlesmile Sues Epic Advertising and Jesse Willms 2
...plements of a fatty acid found in fish oil halves .... Previous research has found that eating oily fis... sudden cardiac death caused by a particular type ...ents. The study found that 1 gram daily of p...
... to a new study shows that women with a specific ...olesterol when they take oestrogen.// Previous res...RT) might protect women from heart disease. Now do...00 women with heart problems who took HRT or place...
...lian psychiatrist has discovered that treating pat...delusions and halucinations.// Although antipsycho... many people still suffer these. But resea...en and it usually strikes them later in life. Stu...
... to study in University of Texas, a novel blood te...sting a possible new way to predict who might get ...edicine in St. Louis said it is unclear whether a ... cause of Alzheimer's. Some people have a genetic ...
...and Drug Administration announced that Vioxx - Mer...ormation on its label. The FDA said that Merck can...ications// than one older non-steroidal anti-infla...h blood pressure. Manufacturer Merck & Compan...
... to researchers at the Mayo Clinic, promote a simp...deal with stress. Hypnotherapy can be a great way ...and relieve pain. Its success depends upon why it ...enefit from a simple form of self hypnosis. ...
Other Medicine News:Health News:Blood test may aid foretell Alzheimer's 2
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
Medicine Products: